Company Overview
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -68.9%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -68.88% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -94.23% |
| 6 Months: | -42.61% |
| 3 Months: | -17.89% |
| 1 Month: | -10.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)44.91 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -68.9% CAGR over 5 years.
- Trading 94.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PLYX Polaryx Therapeutics, Inc. PHARMA | 2.02 | -14.43 | $95.63M | 0.00% | - | -96.56% | - | -68.88% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 5.05M | 884.00K | 974.00K | 911.00K | 1.96M |
| Operating Income | - | -5.05M | -884.00K | -974.00K | -911.00K | -1.96M |
| EBITDA | - | -5.05M | -884.00K | -974.00K | -911.00K | -1.96M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -5.05M | -1.01M | -1.43M | -1.50M | -2.54M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -5.05M | -1.01M | -1.43M | -1.50M | -2.54M |
| Diluted EPS | - | -0.11 | -0.02 | -0.03 | - | -0.05 |
| R&D Expense | - | 4.72M | - | - | - | 679.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Operating Income | -3.78M | -4.35M | -7.82M |
| EBITDA | -3.78M | -4.35M | -7.82M |
| Interest Expense | - | - | - |
| Pretax Income | -3.78M | -30.36M | -8.98M |
| Tax Provision | - | - | - |
| Net Income | -3.78M | -30.36M | -8.98M |
| Diluted EPS | -0.08 | -0.64 | -0.19 |
| R&D Expense | - | 2.81M | 6.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 2.31M | 5.00M | 5.17M |
| Current Assets | 2.31M | 5.00M | 5.17M |
| Cash & Equivalents | 2.00K | 4.62M | 5.14M |
| Inventory | - | - | - |
| Receivables | - | - | - |
| Total Liabilities | 1.04M | 289.00K | 605.00K |
| Current Liabilities | 1.04M | 289.00K | 605.00K |
| Long Term Debt | - | - | - |
| Total Debt | 128.00K | - | - |
| Total Equity | 1.28M | 4.71M | 4.57M |
| Shares Outstanding | 47.34M | 47.34M | 47.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -173.00K | -2.57M | -3.94M |
| Investing Cash Flow | - | - | - |
| Financing Cash Flow | 128.00K | 7.19M | 4.47M |
| Capital Expenditure | - | - | - |
| Free Cash Flow | -173.00K | -2.57M | -3.94M |
| Net Change in Cash | -45.00K | 4.62M | 522.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -295.9% | -644.2% | -196.8% |
| ROCE % | -296.1% | -92.4% | -171.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.33% | 1.66M | $3.38M |
| 2 | Geode Capital Management, LLC | 0.34% | 171.00K | $348.83K |
| 3 | Vanguard Fiduciary Trust Co | 0.21% | 105.07K | $214.35K |
| 4 | HRT Financial LP | 0.16% | 82.09K | $167.47K |
| 5 | State Street Corporation | 0.12% | 58.10K | $118.53K |
| 6 | Blackrock Inc. | 0.08% | 41.01K | $83.66K |
| 7 | Northern Trust Corporation | 0.06% | 27.99K | $57.09K |
| 8 | Jane Street Group, LLC | 0.06% | 31.44K | $64.14K |
| 9 | Allworth Financial LP | 0.02% | 7.73K | $15.76K |
| 10 | Vanguard Global Advisers, LLC | 0.01% | 6.32K | $12.89K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLYX
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBEOEkxVmVGYmRSWWdrTmF1OXpMQ1cyRV90b2VORllLVDB2U2ROdjdFMF9mQ0FOWDRNbkJUQXA0YzRfSlUxaDJfdXdBNGNFRkktb2lJ?oc=5" target="_blank">Polaryx Therapeutics (PLYX) Stock Analysis Report | Fin…
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOY1pDaThsT1lRQjd2Ni1oREpLVXNxZGhQWEJaYU5WeUhIdGhOUktFaUUxLTVQVkEwcFVJMXlBalhRMlplWDVnTkVabVE5a3ZRLVJnbktlMElrQlNGeWxYSVNPNWFvMlFxR2hlaVozakpySjh5ZHQ3eXVZckNIbnR2TDYzSjRtdkpsTUhRUD…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9MWl83QmxVZllZei1OaVFyMWtVNUNBcDdid081TWVjdy1KVnkxaGpaTTBzcmI0Vm9yeUlDaW5veW5VTUYzTU1icHp5R3dEcjY2?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
A pediatric doctor with over 15 years’ experience joins Polaryx - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQWm15djB0SnNDT1VuQ0hVNHFUczVQVFdYTnlIYndleWRZT085emFZS2NVdWlfUEU2UTdoWmxMRTl5NWxfd0RBeG5McU1xeGJIZGZhcERtYmNzcGMyaUNacUpSZkg0X2NhZ0lVNnJKeFpmWERvN3M2Uk1DUWxyYnF2N2hNRnhZeE1DQTlMR3…
$PLYX stock is down 32% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQcXJVV2Q1MlByMmJDNWlPS00yTVBzV1BDRkJVczBrcHZsOHdaLTVoSzJzSXFocXRTN1dpdUlQOWNLNGRhZ2dZQWJ5WXpFNXBLQW1nRkd0aFRmdlBuZTJscVNVMjhiNm96clY1aE9KQkRhNjZXeVoxNl9KdnlJSElKaUk0UnVQRHRYaUxiNj…
PLYX - Polaryx Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5oc0xwWVk3SDhrZklUUmFxUnNkV3I2LWFWUUNFZlY5LTg2WFB0a2NjVlA2Rkpzd0hVa2pERC1ITkE5WXZXOUE?oc=5" target="_blank">PLYX - Polaryx Therapeutics Inc Stock Price and Quote</a> <fo…
PLYX — Frequently Asked Questions
What is the current share price of Polaryx Therapeutics, Inc. (PLYX)?
As of 2026-09-19 21:16 PDT, Polaryx Therapeutics, Inc. (PLYX) trades at $2.02 on NasdaqCM. Its 52-week range is $1.87 to $35.00.
What is the market capitalisation of PLYX?
Polaryx Therapeutics, Inc. (PLYX) has a market capitalisation of $95.63M on NasdaqCM.
What is the P/E ratio of PLYX?
PLYX trades at a trailing price-to-earnings (P/E) ratio of -14.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 9.32.
What is the return on equity (ROE) of PLYX?
PLYX has a return on equity (ROE) of -96.56%.
Is PLYX a good stock to buy?
This page provides a data-driven analysis of Polaryx Therapeutics, Inc. (PLYX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.